AstraZeneca (HAM:ZEG) FFO


HAM:ZEG AstraZeneca PLC HAM:ZEG
87 GF Score
Price €161.90
GF Value €157.31
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is AstraZeneca FFO?

FFO (Funds from operations) only applies to REITs.

HAM:ZEG
87GF Score
AstraZeneca PLC HAM:ZEG
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AstraZeneca (HAM:ZEG) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be overvalued. The current stock price of €161.90 is trading 2.9% above its estimated GF Value™ of €157.31. GuruFocus considers AstraZeneca to be Fairly Valued.

Key valuation signals for HAM:ZEG:

  • FFO:
  • GF Value™: €157.31 vs. price of €161.90 (2.9% above fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the HAM:ZEG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
87GF Score

Get the complete analysis for HAM:ZEG

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€161.90
Price
€157.31
GF Value